Stockreport

Galmed Announces Grant of New Patent for the Combination of Aramchol with Resmetirom (MGL-3196, REZDIFFRA) for the Treatment of NASH and Liver Fibrosis [Yahoo! Finance]

Galmed Pharmaceuticals Ltd. - Ordinary Shares  (GLMD) 
Last galmed pharmaceuticals ltd. - ordinary shares earnings: 3/12 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: galmedpharma.investorroom.com
PDF company for liver, metabolic and fibrotic diseases announced today the grant of a European patent related to the use of a combination of Aramchol and Resmetirom (MGL-319 [Read more]